Clinical Trials Logo

Clinical Trial Summary

Macular GCIPLT and vessel density will be measured with Spectralis optical coherence tomography and Topcon swept-source OCT respectively. Linear, quadratic and exponential regression models will be used to investigate relationship between GCIPLT and vessel density. Multilayer neural network will bel used to make single combined parameter and the diagnostic performance will be also compared.


Clinical Trial Description

This is a prospective, cross-sectional study. All recruited glaucoma patients and healthy subjects will be underwent a complete ophthalmic examination including measurement of the best-corrected visual acuity (BCVA), a slit-lamp examination, gonioscopy, funduscopy, biometry using the IOL Master (Carl Zeiss Meditec, Dublin, CA, USA), and standard automated perimetry (SAP). Central corneal thickness (CCT) will be measured using ultrasonic pachymetry (Pachmate; DGH Technology, Exton, PA, USA). Keratometry will be measured with an Auto Kerato-Refractometer (ARK-510A; NIDEK, Hiroshi, Japan). All of the patients will be also examined using red-free RNFL photographs and optic disc stereoscopic photographs. Two different OCT exam will be performed to measure macular GCIPLT and macular vessel density, spectral domain optic coherence tomography (SD-OCT) and swept source optic coherence tomography angiography (SS-OCTA), respectively.

<Optical Coherence Tomography Angiography Imaging> The macular angiographic images will be obtained using a swept-source OCT (SS-OCT) device (DRI OCT Atlantis; Topcon, Tokyo, Japan). SS-OCT uses infrared light, wavelength of 1050 nm which is longer than conventional SD-OCT, at 100,000 A-scans per second. This longer infrared light source has advantages of deep signal penetration through the retina and choroid. Its axial and transversal resolution is 7 and 20 μm in tissue, respectively. Volumetric OCT scans were taken from 6 × 6 mm cubes. Each cube consists of 320 clusters of 4 repeated B-scans centered on the fovea. Moving objects (mostly blood flows) are detected by measuring intensity fluctuations from these repeatedly scanned OCT images. This methodology is termed as OCTARA (OCT Angiography Ratio Analysis) algorithm where calculations are based on a ratio between the intensity values across points within one scan, and identical points in the repeated scans. OCTARA provides relative sensitivity advantage of the order of 10 ~ 50 times for medium to low blood flow. Automated segmentation was performed by OCT software to separate each layer of the retina. The en-face images of the superficial capillary network were derived from an en-face slab, ranged from the internal limiting membrane (ILM) to the inner border of the inner nuclear layer (INL).

The investigators developed a custom windows software with Microsoft Visual studio 2012 and C# language with a dot net library. This software calculates the sectoral average vessel density exactly matching to the GCIPL sectors. It requires two image files, superficial vascular layer image and color vessel density map, exported from OCTA instrument. Once after two image files were loaded, fovea is automatically detected but in case software fails, user can manually set foveal location. Then, it calculates mean sectoral vessel density between two ellipsoidal boundaries, outer boundary 4800 x 3000 µm and inner boundary 1200 x 1000 µm (width x height) centered on fovea. This diameter of inner and outer ellipse and angle of sectorization is exactly matched to the GCIPL sectorization. The mean vessel density was calculated from color density map. First, custom software scans all pixel colors within the sectoral boundary. Then, each pixel colors are converted to the vessel density values according to the manufacturer's guide. Finally, it takes average of all vessel density values. This mean vessel density is a unitless value ranged from 0 to 100.

<Spectral-Domain Optical Coherence Tomography Imaging> The Cirrus SD-OCT instrument (Carl Zeiss Meditec, Software version 6.0) will be used to measure macular GCIPLT. After pupil dilation using 0.5% tropicamide and 0.5% phenylephrine, a single macular scan (200 × 200 macular cube scan protocol) of each eye was acquired. The GCA algorithm automatically segmented the GCIPL and RNFL and calculated the thickness of the macular GCIPL and RNFL within a 14.13 mm2 elliptical annulus area centered on the fovea. The inner and outer ellipsoidal boundary is exactly matched to the sectoral vessel density calculated by our custom software. Average, minimum, and six sectoral (superotemporal, superior, superonasal, inferonasal, inferior, and inferotemporal) GCIPLT values were obtained. For quality control, the investigators set the minimum signal strength of all included SD-OCT scans to 6.0. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03369886
Study type Interventional
Source Pusan National University Hospital
Contact
Status Recruiting
Phase N/A
Start date September 25, 2017
Completion date August 31, 2018

See also
  Status Clinical Trial Phase
Completed NCT05044793 - A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System
Recruiting NCT06201455 - Evaluation of Phacogoniotomy in Medically-controlled POAG N/A
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Recruiting NCT02679482 - Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma N/A
Completed NCT02338362 - Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma Phase 4
Active, not recruiting NCT01430923 - Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost N/A
Completed NCT01489670 - Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension N/A
Completed NCT00753168 - Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma Phase 1/Phase 2
Completed NCT00693485 - Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy Phase 2
Completed NCT00051194 - A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension Phase 2
Recruiting NCT04920227 - Comparation of CLASS Combined With Phacoemulsification and CLASS Alone in the Treatment of Primary Open Angle Glaucoma N/A
Active, not recruiting NCT03868124 - Clinical Study Comparing Two Models of a Travoprost Intraocular Implant Phase 3
Completed NCT03267862 - Scleral Response to Intraocular Pressure (IOP) N/A
Recruiting NCT06066645 - Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone Phase 3
Recruiting NCT04912362 - The Effectiveness of YAG Iridotomy in Preventing Peripheral Anterior Synechia After CLASS in Primary Open Angle Glaucoma N/A
Completed NCT04949802 - Glaucoma Surgery Using the ViaLase Laser System N/A
Recruiting NCT04038034 - Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients Affected by Primary Open Angle Glaucoma N/A
Completed NCT04632329 - Negative Pressure Applied by the Equinox MPD for Severe Open Angle Glaucoma N/A
Completed NCT01215786 - Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma Phase 1
Completed NCT00801437 - Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.